GMAB Stock Financial Analysis - Genmab A/S (WBAG) Stock

Overview

Genmab A/S, headquartered in Copenhagen, Denmark, operates as a leading biotechnology company focusing primarily on the creation of antibody therapeutics for the treatment of cancer. It is renowned for its innovative approach to antibody technology, particularly through its proprietary platforms such as DuoBody® for dual targeting and HexaBody® for enhanced effector function. A key project includes the development of Daratumumab, an antibody marketed as Darzalex, used in multiple myeloma treatments, which exemplifies Genmab’s capabilities in transforming scientific research into successful therapeutic solutions. The company's dedication to addressing complex medical challenges and its collaborations with major pharmaceutical firms underscore its pivotal role in advancing oncology treatment.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

The revenue for Genmab A/S as of 30 June 2025 is 3,646.88 MM.
The operating income for Genmab A/S as of 30 June 2025 is 1,274.46 MM.
The net income for Genmab A/S as of 30 June 2025 is 1,370.90 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2025-06-30	3,646.88	1,274.46	1,370.90
2025-03-31	3,230.90	1,097.68	1,139.52
2024-12-31	21,526.00	7,079.00	7,844.00
2024-09-30	19,844.00	6,563.00	4,702.00
2024-06-30	2,742.74	881.66	798.29
2024-03-31	2,575.77	825.27	791.06
2023-12-31	16,474.00	5,321.00	4,352.00
2023-09-30	16,852.00	6,183.00	4,163.00
2023-06-30	16,227.00	6,429.00	4,641.00
2023-03-31	15,220.00	6,208.00	5,197.00
2022-12-31	14,505.00	6,267.00	5,452.00
2022-09-30	11,987.00	4,501.00	5,654.00
2022-06-30	10,210.00	3,460.00	3,962.00
2022-03-31	9,020.00	3,000.00	2,377.00
2021-12-31	8,417.00	2,953.00	2,957.00
2021-09-30	7,907.00	3,118.00	2,873.00
2021-06-30	7,321.00	3,086.00	2,513.00
2021-03-31	10,800.00	6,796.00	5,585.00
2020-12-31	10,111.00	6,313.00	4,758.00
2020-09-30	11,028.00	7,602.00	5,649.00
2020-06-30

Income Statement: EPS

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2025-06-30
2025-03-31
2024-12-31	122.21	121.36
2024-09-30	72.74	72.21
2024-06-30	85.11	84.41
2024-03-31	83.75	82.99
2023-12-31	66.64	66.02
2023-09-30	63.76	63.15
2023-06-30	71.09	70.35
2023-03-31	79.50	78.76
2022-12-31	83.38	82.59
2022-09-30	86.43	85.63
2022-06-30	60.54	59.98
2022-03-31	36.33	35.99
2021-12-31	45.22	44.77
2021-09-30	43.93	43.50
2021-06-30	38.45	38.05
2021-03-31	85.60	84.69
2020-12-31	73.00	72.21
2020-09-30	86.82	85.83
2020-06-30	87.26	86.41

Cash Flow: Operations, Investing, Financing

The cash from operating activities for Genmab A/S as of 30 June 2025 is 1,134.40 MM.
The cash from investing activities for Genmab A/S as of 30 June 2025 is -96.68 MM.
The cash from financing activities for Genmab A/S as of 30 June 2025 is -510.98 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2025-06-30	1,134.40	-96.68	-510.98
2025-03-31	1,193.94	-1,268.43	-495.82
2024-12-31	7,771.00	-9,907.00	-3,919.00
2024-09-30	6,731.00	-10,431.00	-3,944.00
2024-06-30	970.89	-1,398.68	-525.29
2024-03-31	818.50	-393.54	-84.28
2023-12-31	7,380.00	-1,282.00	-606.00
2023-09-30	6,106.00	-976.00	-453.00
2023-06-30	6,037.00	-3,366.00	-1,115.00
2023-03-31	6,560.00	-2,107.00	-1,336.00
2022-12-31	3,912.00	-2,761.00	-789.00
2022-09-30	3,755.00	-2,931.00	-904.00
2022-06-30	2,234.00	-3,170.00	-238.00
2022-03-31	1,630.00	-1,049.00	-264.00
2021-12-31	2,228.00	-961.00	-420.00
2021-09-30	1,189.00	-1,369.00	-403.00
2021-06-30	5,820.00	-2,313.00	-408.00
2021-03-31	5,704.00	-2,939.00	-164.00
2020-12-31	6,433.00	-2,351.00	71.00
2020-09-30	7,406.00	-2,788.00	46.00
2020-06-30

Valuation Metrics : PE, PriceToBook, PriceToTBV

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30

Management Effectiveness

The roa for Genmab A/S as of 30 June 2025 is 0.03.
The roe for Genmab A/S as of 30 June 2025 is 0.04.
The roic for Genmab A/S as of 30 June 2025 is 0.21.
The croic for Genmab A/S as of 30 June 2025 is -0.08.
The ocroic for Genmab A/S as of 30 June 2025 is 0.22.

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC
2025-06-30	0.03	0.04	0.21	-0.08	0.22
2025-03-31	0.21	0.24	0.21	-0.13	0.21
2024-12-31	0.13	0.25	0.14	-0.24	0.20
2024-09-30	0.16	0.15	0.17	-0.20	0.21
2024-06-30	0.18	0.20	0.16	0.07	0.17
2024-03-31	0.14	0.16	0.13	0.15	0.23
2023-12-31	0.14	0.16	0.13	0.12	0.19
2023-09-30	0.17	0.19	0.16	0.04	0.20
2023-06-30	0.19	0.19	0.16	0.04	0.20
2023-03-31	0.22	0.23	0.19	0.11	0.23
2022-12-31	0.24	0.27	0.21	0.06	0.14
2022-09-30	0.17	0.27	0.21	0.06	0.14
2022-06-30	0.11	0.20	0.16	0.01	0.09
2022-03-31	0.14	0.12	0.10	0.05	0.07
2021-12-31	0.14	0.16	0.13	0.08	0.05
2021-09-30	0.13	0.16	0.13	-0.01	0.28
2021-06-30	0.12	0.14	0.12	0.14	0.28
2021-03-31	0.36	0.39	0.27	0.11	0.28
2020-12-31	0.31	0.34	0.24	0.19	0.33
2020-09-30	0.42	0.68	0.30	0.23	0.39
2020-06-30	0.63	0.68	0.31	0.33	0.15

Gross Margins

The gross margin for Genmab A/S as of 30 June 2025 is 0.95.
The net margin for Genmab A/S as of 30 June 2025 is 0.35.
The operating margin for Genmab A/S as of 30 June 2025 is 0.34.

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin
2025-06-30	0.95	0.35	0.34
2025-03-31	0.95	0.36	0.33
2024-12-31	0.96	0.24	0.33
2024-09-30	0.97	0.29	0.33
2024-06-30	0.98	0.31	0.32
2024-03-31	0.99	0.26	0.32
2023-12-31	0.99	0.25	0.37
2023-09-30	1.00	0.29	0.40
2023-06-30	1.00	0.29	0.40
2023-03-31	1.00	0.35	0.41
2022-12-31	1.00	0.47	0.38
2022-09-30	1.00	0.47	0.38
2022-06-30	1.00	0.39	0.34
2022-03-31	1.00	0.26	0.33
2021-12-31	1.00	0.35	0.36
2021-09-30	1.00	0.36	0.39
2021-06-30	1.00	0.34	0.42
2021-03-31	1.00	0.52	0.63
2020-12-31	1.00	0.47	0.63
2020-09-30	1.00	0.51	0.69
2020-06-30	1.00	0.55	0.69

US:GNMSF
MX:GMAB N
GB:0MGB	DKK 1.760,25
GB:GMABC
DK:GMAB	DKK 1.640,50
DE:GE9	€ 234,30